Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mouse tyrosinase-related protein 2 DNA vaccine
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramuscular
01
Overview
The mouse tyrosinase-related protein 2 (mTRP-2) DNA vaccine is a xenogeneic cancer immunotherapy designed to treat malignant melanoma. It consists of a plasmid DNA vector encoding the murine version of the tyrosinase-related protein 2, an enzyme involved in melanin biosynthesis that is highly expressed in melanoma cells. The vaccine utilizes the principle of xenogeneic immunization; because the mouse TRP-2 protein is highly homologous but not identical to the human TRP-2 protein, it acts as a foreign antigen to circumvent the immune system's self-tolerance. Upon administration, the plasmid is taken up by host cells, leading to the expression of mTRP-2, which stimulates the production of cytotoxic T lymphocytes (CTLs) and antibodies that cross-react with the endogenous human TRP-2 on tumor cells, ultimately promoting tumor regression.
- Other names
- xenogeneic TRP-2 DNA vaccinemTRP-2 DNA vaccinemTRP2 DNA vaccinemTRP 2 DNA vaccinemouse TRP-2 DNA vaccineDNA vaccine encoding mouse tyrosinase-related protein 2
02
Targets
TYRP2 (Tyrosinase-related Protein 2)
Beyond the preview
Go deeper on mouse tyrosinase-related protein 2 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mouse tyrosinase-related protein 2 DNA vaccine.